{"nctId":"NCT00759811","briefTitle":"METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)","startDateStruct":{"date":"2007-12"},"conditions":["Heart Failure","Myocardial Ischemia"],"count":50,"armGroups":[{"label":"Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Methotrexate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Methotrexate","otherNames":["Rheumatrex","Trexall"]},{"name":"Placebo","otherNames":["Control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Heart failure functional class measured using the New York Heart Association classification class II, III or IV\n* Left ventricular fraction \\<0.45 at the ventriculography\n* Angiographic coronary lesions higher than 50% or coronary lesion revascularized (coronary artery bypass or percutaneous transluminal coronary angioplasty)\n\nExclusion Criteria:\n\n* Myocardial infarction in the past four months\n* Coronary artery bypass or percutaneous transluminal coronary angioplasty in the past four months\n* Left ventricular disfunction diagnosed during a acute coronary syndrome\n* Those who require revascularization in the following 12 weeks\n* Hepatic disease (ALT and AST higher than the upper limit of the reference value)\n* Renal failure (plasma creatinine higher than 2.0mg/dl)\n* Alcoholism (20 doses per week or more)\n* Illegal drug use\n* Rheumatoid arthritis or other inflammatory diseases\n* Infectious disease\n* Neoplasm\n* Anemia (hematocrit lower than 30%)\n* Currently on any anti-inflammatory drugs\n* Difficulty in walking\n* Unable to understand/complete the 36-item Short Form health survey (SF-36)\n* Those who do not give informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Physical Capacity Measured Using the 6-minute Walk Test Distance","description":"The primary outcome of the study was the difference in 6MWT distance before and after the treatment (change in meters evaluated by t test).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":"39.5"},{"groupId":"OG001","value":"21.3","spread":"43.7"}]}]}]},{"type":"SECONDARY","title":"Improve in Heart Failure Functional Class Measured Using New York Heart Association","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Improve in Quality of Life Measured Using the Brazilian Edition SF-36","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Reduction of Inflammatory Marker Measured Using C-reactive Protein Blood Levels","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of All Cause Mortality, Hospitalization for Worsening Heart Failure, Myocardial Infarct, Stroke or Myocardial Revascularization Need","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Adverse Effects of the Treatment","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["dizziness","nausea","lipothymia","sustained ventricular tachycardia"]}}}